Immunotherapy: State-of-the-art review of therapies and theratypes

Agache, Ioana; Zemelka‐Wiącek, Magdalena; Shamji, Mohamed H.; Jutel, Marek

doi:10.1016/j.jaci.2022.10.007

Cited by 13 publications

(10 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They include conditions caused by hypersensitivity of the immune system elicited by otherwise harmless environmental substances. Although classically, the mechanisms of allergies are associated with T2 responses, recent discoveries showed endotypes of allergic diseases related to T1 or T3‐driven activation pathways, 34–36 which were originally assumed to be involved in a variety of immune‐mediated diseases including autoimmunity characterized by mechanisms distinct from allergies 37 …”

Section: Introductionmentioning

confidence: 99%

“…Although classically, the mechanisms of allergies are associated with T2 responses, recent discoveries showed endotypes of allergic diseases related to T1 or T3-driven activation pathways, [34][35][36] which were originally assumed to be involved in a variety of immune-mediated diseases including autoimmunity characterized by mechanisms distinct from allergies. 37 Allergy is an abnormal or exaggerated reaction to exogenous stimuli which involves various types of hypersensitivity reactions engaging antibodies, immune cell-mediated, tissue-driven or metabolic mechanisms resulting in the development of respiratory, skin, eye, gastrointestinal and other symptoms, including anaphylaxis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

Jutel,

Agache,

Zemelka‐Wiacek

et al. 2023

Allergy

Self Cite

View full text Add to dashboard Cite

The exponential growth of precision diagnostic tools, including omic technologies, molecular diagnostics, sophisticated genetic and epigenetic editing, imaging and nano‐technologies and patient access to extensive health care, has resulted in vast amounts of unbiased data enabling in‐depth disease characterization. New disease endotypes have been identified for various allergic diseases and triggered the gradual transition from a disease description focused on symptoms to identifying biomarkers and intricate pathogenetic and metabolic pathways. Consequently, the current disease taxonomy has to be revised for better categorization. This European Academy of Allergy and Clinical Immunology Position Paper responds to this challenge and provides a modern nomenclature for allergic diseases, which respects the earlier classifications back to the early 20th century. Hypersensitivity reactions originally described by Gell and Coombs have been extended into nine different types comprising antibody‐ (I‐III), cell‐mediated (IVa‐c), tissue‐driven mechanisms (V‐VI) and direct response to chemicals (VII). Types I‐III are linked to classical and newly described clinical conditions. Type IVa‐c are specified and detailed according to the current understanding of T1, T2 and T3 responses. Types V‐VI involve epithelial barrier defects and metabolic‐induced immune dysregulation, while direct cellular and inflammatory responses to chemicals are covered in type VII. It is notable that several combinations of mixed types may appear in the clinical setting. The clinical relevance of the current approach for allergy practice will be conferred in another article that will follow this year, aiming at showing the relevance in clinical practice where various endotypes can overlap and evolve over the lifetime.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

Jutel,

Agache,

Zemelka‐Wiacek

et al. 2023

Allergy

Self Cite

View full text Add to dashboard Cite

show abstract

“…Immunotherapy is revolutionizing the treatment landscape of various solid tumors, including chimeric antigen receptor T cell therapy (CAR-T), cancer vaccines, oncolytic viruses, and immune checkpoint inhibitors (ICB) [3] . Among these, ICB agents, such as cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitors, programmed cell death protein-1 (PD-1) inhibitors, and programmed cell death-ligand 1 (PD-L1) inhibitors, have found widespread clinical application [4] .…”

Section: Introductionmentioning

confidence: 99%

Exploring GZMK as a Prognostic Marker and Predictor of Immunotherapy Response in Breast Cancer: Unveiling Novel Insights into Treatment Outcomes

Li,

Xie,

Zhao

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Granzyme K (GZMK) is an important mediator released by immune cells to eliminate tumor cells and plays crucial roles in inflammation and tumorigenesis. However, the precise role of GZMK in breast cancer and its underlying mechanisms remain poorly understood. Methods Utilizing data from TCGA and GEO databases, along with various analytical approaches including GO, KEGG, GSEA, ssGSEA, and PPI, we investigated the impact of GZMK on breast cancer. RT-qPCR, CCK-8 assay, cell cycle experiments, apoptosis assays, Celigo scratch assays, Transwell assays, and immunohistochemical methods were employed to validate the in vitro effects of GZMK on breast cancer. Furthermore, Cox regression analysis based on TCGA data and our clinical data was conducted to establish an overall survival (OS) prediction model for breast cancer. Results We observed elevated expression of GZMK in breast cancer tissues, particularly in subanalyses showing higher expression in hormone receptor-negative and HER2-positive patients. Clinical pathological feature analysis revealed significant correlations between GZMK expression and lymph node staging, differentiation grade, and molecular subtypes of breast cancer. High expression of GZMK was associated with improved OS, progression-free survival (PFS), and recurrence free survival (RFS) in patients, as confirmed by multifactor Cox regression analysis indicating that GZMK_High improves patient OS. Functional and pathway enrichment analysis of genes positively correlated with GZMK revealed involvement in lymphocyte differentiation, T cell differentiation, and T cell receptor signaling pathways. Analysis of immune cell infiltration in the breast cancer tumor microenvironment (TME) demonstrated a strong association between GZMK expression and T cells, as well as favorable correlations with ESTIMATEScore_estimate (Cor = 0.743, P < 0.001), ImmuneScore_estimate (Cor = 0.802, P < 0.001), and StromalScore_estimate (Cor = 0.516, P < 0.001). Moreover, GZMK exhibited significant correlations with immune checkpoint molecules including CTLA4 (Cor = 0.856, P < 0.001), PD-1 (Cor = 0.82, P < 0.001), PD-L1 (Cor = 0.56, P < 0.001), CD48 (Cor = 0.75, P < 0.001), and CCR7 (Cor = 0.856, P < 0.001). Three immune-related studies suggested that high expression of GZMK enhances patients' responsiveness to immunotherapy, with higher levels observed in immunotherapy-responsive patients compared to non-responsive ones. In vitro experiments validated that GZMK enhances cell proliferation, promotes cell division, facilitates apoptosis, increases cell migration capacity, and enhances cell invasiveness. Conclusion Our study provides insights into the differential expression of GZMK in breast cancer and offers preliminary insights into its potential mechanisms in breast cancer pathogenesis. Elevated GZMK expression improves OS and RFS in breast cancer patients, suggesting its potential as a prognostic marker for breast cancer survival and as a predictor of immunotherapy efficacy in tumor patients.

show abstract

“…Photothermal therapy (PTT) [ 13 , 14 ], chemodynamic therapy (CDT) [ 15 , 16 ], immunotherapy [ 17 , 18 , 19 ], and a combination of two or more therapies can reduce the risk of side effects and enhance anti-cancer efficacy [ 20 , 21 , 22 , 23 , 24 ]. The detection of characteristic cancer markers and bioimaging in cancer therapy are important components of current cancer treatment [ 25 , 26 , 27 ].…”

Section: Introductionmentioning

confidence: 99%

Porous Framework Materials for Bioimaging and Cancer Therapy

et al. 2023

View full text Add to dashboard Cite

Cancer remains one of the most pressing diseases in the world. Traditional treatments, including surgery, chemotherapy, and radiotherapy still show certain limitations. Recently, numerous cancer treatments have been proposed in combination with novel materials, such as photothermal therapy, chemodynamic therapy, immunotherapy, and a combination of therapeutic approaches. These new methods have shown significant advantages in reducing side effects and synergistically enhancing anti-cancer efficacy. In addition to the above approaches, early diagnosis and in situ monitoring of lesion areas are also important for reducing side effects and improving the success rate of cancer therapy. This depends on the decent use of bioimaging technology. In this review, we mainly summarize the recent advances in porous framework materials for bioimaging and cancer therapy. In addition, we present future challenges relating to bioimaging and cancer therapy based on porous framework materials.

show abstract

Immunotherapy: State-of-the-art review of therapies and theratypes

Cited by 13 publications

References 90 publications

Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

Exploring GZMK as a Prognostic Marker and Predictor of Immunotherapy Response in Breast Cancer: Unveiling Novel Insights into Treatment Outcomes

Porous Framework Materials for Bioimaging and Cancer Therapy

Contact Info

Product

Resources

About